Home » Stocks » IPCIF

Intellipharmaceutics International Inc. (IPCIF)

Stock Price: $0.2197 USD 0.0097 (4.62%)
Updated Jun 15, 2021 12:49 PM EDT - Market closed
Market Cap 6.22M
Revenue (ttm) 1.40M
Net Income (ttm) -3.39M
Shares Out 33.09M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 15
Last Price $0.2197
Previous Close $0.2100
Change ($) 0.0097
Change (%) 4.62%
Day's Open 0.2000
Day's Range 0.2000 - 0.2197
Day's Volume 3,226
52-Week Range 0.0588 - 0.4800

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TORONTO, ON / ACCESSWIRE / April 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...

1 month ago - Accesswire

TORONTO, ON / ACCESSWIRE / April 14, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resear...

2 months ago - Accesswire

TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...

3 months ago - Accesswire

TORONTO, ON / ACCESSWIRE / December 23, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...

5 months ago - Accesswire

About IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for... [Read more...]

Industry
Biotechnology
Founded
1998
CEO
Isa Odidi
Employees
13
Stock Exchange
OTCMKTS
Ticker Symbol
IPCIF
Full Company Profile

Financial Performance

In 2020, IPCIF's revenue was $1.40 million, a decrease of -59.73% compared to the previous year's $3.48 million. Losses were -$3.39 million, -58.06% less than in 2019.

Financial Statements